Clinical Trials - The Effect of Naloxegol in Cancer Opioid-Induced Constipation - Constipation
Opioid-induced constipation (OIC) is a common symptom in patients. Naloxegol has been proved to be helpful in relieving the pain caused by cancer. The purpose of this study is to compare the effect of naloxegol versus the patient’s usual care in treating opioid-induced constipation, as well as the effect on the patient’s quality of life and how much pain is experienced.
| Study Type : | Interventional  (Clinical Trial) |
| Estimated Enrollment : | 60 participants |
| Allocation: | Randomized |
| Intervention Model: | Crossover Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase II, Randomized, Single Center, Pilot Feasibility Study to Evaluate Naloxegol for Opioid-Induced Constipation in Cancer Patients |
| Study Start Date : | May 2016 |
| Estimated Primary Completion Date : | April 2020 |
| Estimated Study Completion Date : | April 2021 |
Contacts
| Contact: Chelsea Hagmann | chagmann@ucsd.edu |
| ClinicalTrials.gov Identifier: | NCT02745353 |
For enrollment please visit www.clinicaltrials.gov.
* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.